Bristol-Myers Squibb: The Market Is Not Pricing The Growth Portfolio That Replaces The Patent Cliff

Bristol-Myers Squibb (BMY) looks undervalued at 8.9x forward P/E; see growth catalysts, FDA/Phase 3 timelines, and a $68 ...
Manila Bulletin

UAAP launches golf tourney at TCC

Golf is finally making its much-anticipated entry into the UAAP mainstream, debuting as a demonstration event this Season 88 – a significant step ...
Daily SunOpinion

Rooppur and the Recasting of Bangladesh’s Energy Future

It is a strategically consequential moment in the country’s long search for energy security, supply stability, and economic ...